首页 | 本学科首页   官方微博 | 高级检索  
     


EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer
Affiliation:1. Cancer Diagnosis and Pathology Group, Northern Translational Cancer Research Unit, Kolling Institute of Medical Research, St Leonards, Australia;2. Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia;3. Sydney Medical School, University of Sydney, Sydney, Australia;4. HistoPath Pathology, North Ryde, Australia;5. Tissue Oncology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, Australia;6. School of Medicine, University of Western Sydney, Sydney, Australia;7. Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia;8. Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australia;9. University of NSW, Sydney, Australia;10. Department of Anatomical Pathology, SydPath, St Vincent’s Hospital, Darlinghurst, NSW, Australia;1. PathWest, Queen Elizabeth II Medical Centre, Nedlands, and University of Western Australia, WA, Australia;2. Envoi Pathology, Herston, Qld, Australia;3. Sir Charles Gairdner Hospital, Nedlands, WA, Australia;4. Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, and Westmead Clinical School, University of Sydney, Sydney, NSW, Australia;5. Department of Histopathology, The Children’s Hospital at Westmead, Sydney, NSW, Australia;6. Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia;7. St John of God Hospital Murdoch, Murdoch, and Department of Surgery, Fremantle Hospital, Fremantle, WA, Australia;8. Cancer Diagnosis and Pathology Group, University of Sydney, NSW, Australia;9. Griffith Medical School and Griffith Health Institute, Griffith University, Qld, Australia;10. Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia;11. St. Michael’s Hospital, Toronto, Canada;12. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States;1. Department of Surgery, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia;2. University Malaya Cancer Research Institute (UMCRI), Kuala Lumpur, Malaysia;3. Centre for Kidney Disease Research, School of Medicine, The University of Queensland, Translational Research Institute, Brisbane, Qld, Australia;4. Department of Pathology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia;5. University Malaya Medical Centre, Kuala Lumpur, Malaysia;1. Department of Clinical Haematology, Monash Medical Centre, Clayton, Australia;2. Department of Infectious Diseases, Monash Medical Centre, Clayton, Australia;3. Refugee Health Service, Monash Health, Vic, Australia;1. Department of Laboratory Animal Science, School of Medicine, Shanghai Jiao Tong University, Shanghai, P. R. China;2. Monell Chemical Senses Center, Philadelphia, PA, United States;1. Department of Pathology, Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China;2. Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China;3. Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong SAR, China;4. Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China;1. Radiation Oncology Department, Oncology Hospital, Centro Medico Nacional Siglo XXI (IMSS), Mexico, D.F., Mexico;2. Pathology Department, National Cancer Institute of Mexico (INCan), Mexico, D.F., Mexico;3. Radiation Oncology Department, National Cancer Institute of Mexico (INCan), Mexico, D.F., Mexico;4. Radiation Oncology Department, Catalan Institute of Oncology (ICO-L''Hospitalet), Barcelona, Spain;5. Radiation Oncology Department, Medica Sur Hospital, Mexico, D.F., Mexico
Abstract:
Keywords:EGFR immunohistochemistry  EGFR inhibitors  erlotinib  gefitininb  lung cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号